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Quite reasonably, patients with bipolar disorder 
want treatment that provides sustained relief from 
their illness without incurring serious side-eﬀ ects. 
Functionally, this translates to the resumption of 
purpose and enjoyment. But of the numerous drugs 
available for the management of bipolar disorder, only 
lithium seems to truly stabilise mood.1 Its status as an 
eﬀ ective prophylactic agent was convincingly reinstated 
by the ﬁ ndings of the randomised, open-label BALANCE 
trial,2 which corroborated empirical knowledge. The 
BALANCE investigators showed that lithium alone, or 
lithium plus valproate, are more likely to prevent relapse 
than valproate monotherapy, and prophylaxis with 
lithium monotherapy might be on a par with lithium 
plus valproate. Hence, despite ﬂ uctuating popularity, 
lithium remains a ﬁ rst-line option for the treatment 
and prophylaxis of bipolar disorder in therapeutic 
guidelines.3 However, use of lithium in practice is limited 
by concerns about safety and adverse eﬀ ects with 
long-term use.
Extending previous research that examined the 
short-term tolerability of lithium,4 in The Lancet 
Brian Shine and colleagues5 have drawn on a large 
set of data to determine the long-term eﬀ ects of 
lithium on renal and endocrine function. Data from 
4678 patients were included in the study, of whom 
2795 had their serum lithium measured more than 
once. Shine and colleagues’ ﬁ ndings show that 
lithium was associated with increased risk of stage 
three chronic kidney disease (estimated glomerular 
ﬁ ltration rate <60 mL/min/1·73m²; hazard ratio 1·93, 
95% CI 1·76–2·12), hypothyroidism (thyrotropin activity 
>5·5 mU/L; 2·31, 2·05–2·60), and hypercalcaemia 
(1·43, 1·21–1·69). These ﬁ ndings send a key message 
to clinicians to monitor lithium therapy closely from 
the outset. Both thyroid hormone secretion and renal 
function can decline with long-term lithium use and can, 
in some cases, lead to hypothyroidism and stage three 
chronic kidney disease. Interestingly, these complications 
are more likely to occur in women than in men, and 
are detected early in the course of lithium treatment. 
In addition, long-term lithium therapy can also cause 
hypercalcaemia (ie, total plasma calcium concentration 
≥2·6 mmol/L). All adverse eﬀ ects are more likely to 
occur when plasma lithium concentration is high. 
Therefore, patients receiving lithium therapy should 
have thyroid function, renal clearance, and blood calcium 
concentrations assessed carefully at the beginning of 
therapy and monitored closely thereafter. Shine and 
colleagues5 provide clear evidence of the potential 
risks associated with long-term lithium treatment. 
But because bipolar disorder typically emerges at a 
young age6 and requires lifelong treatment, these 
ﬁ ndings prompt the question: how can these hazards be 
navigated?
The answer is twofold. First, avoid sustained periods 
during which plasma lithium concentrations are high 
to diminish the risk of serious adverse eﬀ ects. Second, 
all the parameters that need regular assessment, such 
as thyroid and renal function tests and plasma lithium 
and calcium concentrations, can be measured reliably 
and easily. However, the treatment of type I bipolar 
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Figure: The Lithium Membrain by Anne Naylor
Lithium coursing through veins in the brain (blue) provides mood stability by 
acting as a membrane that prevents the eﬀ ects of the various faces of the illness 
(circles) on the brain (neural networks).
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disorder, the subtype best suited to lithium therapy,7 is 
often complicated by comorbid anxiety and substance 
misuse. Furthermore, lithium’s therapeutic eﬀ ect occurs 
at concentrations that can be toxic if maintained in the 
long term.8 These concerns reinforce a widely held view 
that lithium therapy is problematic. But all drugs are 
associated with side-eﬀ ects, and long-term management 
often involves a risk–beneﬁ t analysis at some point in the 
treatment course; lithium is no exception.
Maintenance of lithium concentrations at the lower 
end of the therapeutic range (ie, 0·6 mmol/L) can 
reduce the adverse outcomes associated with lithium 
treatment. For plasma lithium concentrations to 
be high enough to be eﬃ  cacious, but low enough 
to avoid toxicity, is a delicate balance. The simple 
pharmacokinetics of lithium in plasma oﬀ er some 
assistance, but the pharmacokinetics of lithium within 
the brain are more complex because the blood–brain 
barrier insulates the brain from rapid changes in plasma 
lithium concentration and facilitates its accumulation 
in neural tissues, which can be neurotoxic.9 The 
movement of lithium between plasma, cerebrospinal 
ﬂ uid, and brain tissue is not fully understood, and 
future research will need to examine the eﬀ ects of 
diﬀ erent doses and duration of lithium treatment on 
concentrations within these various compartments. For 
example, a low concentration of lithium in the plasma 
(0·2–0·4 mmol/L) has little eﬀ ect on renal and thyroid 
function,10 and is achievable with alternate-day dosing.9
Lithium is without doubt the best treatment for 
many patients with bipolar disorder because it confers 
long-term mood stability and prophylaxis (ﬁ gure). 
Lithium also reduces the risk of suicide11 and is possibly 
neuroprotective.12 The dilemma of lithium therapy arises 
because, if poorly managed, lithium can compromise 
renal function, sometimes irreversibly, and severely 
disrupt endocrine homoeostasis—ultimately limiting 
its usefulness. Therefore, lithium therapy remains a 
challenge that will beneﬁ t from a better understanding 
of its therapeutic properties.
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